GSB Wealth Management’s Moderna MRNA Stock Holding History

GSB Wealth Management’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.06M	Buy	15,145 +5	+0%	+$259	0.21%	105
2026 Q1	$769K	Buy	15,140 +15	+0.1%	+$700	0.17%	116
2025 Q4	$446K	Buy	15,125 +4,850	+47%	+$132K	0.1%	149
2025 Q3	$265K	Sell	10,275 -30	-0.3%	-$837	0.06%	202
2025 Q2	$284K	Buy	10,305 +1,995	+24%	+$52.5K	0.07%	189
2025 Q1	$236K	Sell	8,310 -1,991	-19%	-$70.7K	0.06%	196
2024 Q4	$428K	Buy	10,301 +5,009	+95%	+$239K	0.11%	147
2024 Q3	$354K	Buy	5,292 +2,000	+61%	+$184K	0.09%	166
2024 Q2	$391K	Hold	3,292	–	–	0.11%	155
2024 Q1	$351K	Hold	3,292	–	–	0.1%	163
2023 Q4	$327K	Buy	+3,292	New	+$277K	0.1%	160
2023 Q3	–	Sell	-1,792	Closed	-$218K	–	201
2023 Q2	$218K	Buy	+1,792	New	+$239K	0.07%	195
2021 Q3	–	Sell	-915	Closed	-$215K	–	192
2021 Q2	$215K	Buy	+915	New	+$164K	0.07%	210

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

GSB Wealth Management's MRNA Position: Q2 2026 in Review

GSB Wealth Management increased its Moderna (MRNA) stake by 0.03% in Q2 2026, buying an estimated $259 and bringing the position to 15,145 shares worth $1.06M. The position accounts for 0.21% of the portfolio, ranked #105.

GSB Wealth Management first reported a position in MRNA in Q2 2021 and has held it in 13 quarters since. 784 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

GSB Wealth Management held 15,145 shares of Moderna worth $1.06M as of Q2 2026.
GSB Wealth Management bought 5 Moderna shares in Q2 2026, an estimated $259.
Moderna made up 0.21% of GSB Wealth Management's portfolio in Q2 2026, its #105 holding.
GSB Wealth Management first reported a position in Moderna in Q2 2021 and has held it in 13 quarters since.
784 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on GSB Wealth Management's 13F filing for Q2 2026, filed 27 Jul 2026.